Teva launches generic Exforge HCT tabs

JERUSALEM — Teva Pharmaceutical on Monday announced the launch of a generic version of Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the United States. Teva was first to file for the generic, according to the company. 

 

Exforge HCT tablets, which are marketed by Novartis, had annual sales in the United States of approximately $158 million as of September 2014, according to IMS Health data.